 Nadejda Valiaeva
|
|
| Title(s) | Associate Project Scientist, Medicine |
|---|
| School | Vc-health Sciences-schools |
|---|
| Address | 9500 Gilman Drive #0711
La Jolla CA 92093
|
|---|
| Phone | 000-000-NULL |
|---|
| vCard | Download vCard |
|---|
|
|
 Bibliographic
Altmetrics Details
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
Rethinking Remdesivir: Synthesis of Lipid Prodrugs that Substantially Enhance Anti-Coronavirus Activity. bioRxiv. 2020 Aug 27.
Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang XQ, Garretson AF, Smith VI, Murphy J, Hostetler KY. PMID: 32869033.
View in: PubMed Mentions:
-
Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate. Antiviral Res. 2019 11; 171:104614.
Beadle JR, Aldern KA, Zhang XQ, Valiaeva N, Hostetler KY, Schooley RT. PMID: 31550449.
View in: PubMed Mentions: Fields: Translation: HumansCells
-
Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro. Antiviral Res. 2018 10; 158:122-126.
Kumaki Y, Woolcott JD, Roth JP, Mclean TZ, Smee DF, Barnard DL, Valiaeva N, Beadle JR, Hostetler KY. PMID: 30096340.
View in: PubMed Mentions: Fields: Translation: HumansCellsPHPublic Health
-
Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification. J Med Chem. 2016 12 08; 59(23):10470-10478.
Beadle JR, Valiaeva N, Yang G, Yu JH, Broker TR, Aldern KA, Harden EA, Keith KA, Prichard MN, Hartman T, Buckheit RW, Chow LT, Hostetler KY. PMID: 27933957.
View in: PubMed Mentions: 2 Fields: Translation: HumansCells
-
A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate for proliferative vitreoretinopathy. Mol Vis. 2012; 18:1907-17.
Kim JS, Beadle JR, Freeman WR, Hostetler KY, Hartmann K, Valiaeva N, Kozak I, Conner L, Trahan J, Aldern KA, Cheng L. PMID: 22876115.
View in: PubMed Mentions: 6 Fields: Translation: HumansAnimalsCells
-
Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action. Antimicrob Agents Chemother. 2011 Nov; 55(11):5063-72.
Magee WC, Valiaeva N, Beadle JR, Richman DD, Hostetler KY, Evans DH. PMID: 21896914.
View in: PubMed Mentions: 2 Fields: Translation: HumansCells
-
Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. Bioorg Med Chem. 2011 Aug 01; 19(15):4616-25.
Valiaeva N, Wyles DL, Schooley RT, Hwu JB, Beadle JR, Prichard MN, Hostetler KY. PMID: 21719300.
View in: PubMed Mentions: 4 Fields: Translation: HumansCells
-
Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation. Mol Vis. 2011 Mar 02; 17:627-37.
Hou J, Li Y, Zhou Z, Valiaeva N, Beadle JR, Hostetler K, Freeman WR, Hu DN, Chen H, Cheng L. PMID: 21386925.
View in: PubMed Mentions: 4 Fields: Translation: HumansCells
-
Antiproliferative effects of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine against Me-180 human cervical cancer cells in vitro and in vivo. Chemotherapy. 2010; 56(1):54-9.
Valiaeva N, Trahan J, Aldern KA, Beadle JR, Hostetler KY. PMID: 20215748.
View in: PubMed Mentions: Fields: Translation: HumansAnimalsCells
-
Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses. Antiviral Res. 2009 Dec; 84(3):254-9.
Valiaeva N, Prichard MN, Buller RM, Beadle JR, Hartline CB, Keith KA, Schriewer J, Trahan J, Hostetler KY. PMID: 19800369.
View in: PubMed Mentions: 4 Fields: Translation: HumansAnimalsCells
-
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro. Antimicrob Agents Chemother. 2009 Dec; 53(12):5284-7.
Botros SS, William S, Beadle JR, Valiaeva N, Hostetler KY. PMID: 19704122.
View in: PubMed Mentions: 5 Fields: Translation: AnimalsCells
-
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates. Antimicrob Agents Chemother. 2008 Dec; 52(12):4326-30.
Prichard MN, Hartline CB, Harden EA, Daily SL, Beadle JR, Valiaeva N, Kern ER, Hostetler KY. PMID: 18852272.
View in: PubMed Mentions: 5 Fields: Translation: HumansCells
-
Synthesis and antiviral evaluation of alkoxyalkyl esters of acyclic purine and pyrimidine nucleoside phosphonates against HIV-1 in vitro. Antiviral Res. 2006 Oct; 72(1):10-9.
Valiaeva N, Beadle JR, Aldern KA, Trahan J, Hostetler KY. PMID: 16630664.
View in: PubMed Mentions: 10 Fields: Translation: HumansCells
-
Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 2005 Feb; 49(2):656-62.
Wan WB, Beadle JR, Hartline C, Kern ER, Ciesla SL, Valiaeva N, Hostetler KY. PMID: 15673748.
View in: PubMed Mentions: 28 Fields: Translation: HumansAnimalsCells
This graph shows the total number of publications by year. To see the data as text, click here.
This graph shows the total number of publications by year. To return to the graph, click here.
| Year | Publications |
|---|
| 2005 | 1 | | 2006 | 1 | | 2008 | 1 | | 2009 | 2 | | 2010 | 1 | | 2011 | 3 | | 2012 | 1 | | 2016 | 1 | | 2018 | 1 | | 2019 | 1 | | 2020 | 1 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs
|
Derived automatically from this person's publications.
_
People in Profiles who have published with this person.
_
People who share similar concepts with this person.
_
Search Department
_
|